Consistent with the idea that S1P possesses vasoprotective properties, apoM knockout mice were reportedly prone to atherosclerosis. 23 Therefore, S1P and apoM could be promising targets to improve HDL functions.
H igh-density lipoprotein (HDL) is a target for preventing atherosclerotic diseases, in addition to low-density lipoprotein (LDL) cholesterol. 1, 2 Although the LDL cholesterol level can be well controlled with currently available medicines, such as statins and ezetimibe, drugs that target the quantity and quality of HDL have not yet been introduced into clinical medicine. 3, 4 Therefore, it is a very important task to elucidate the dynamics and functions of HDL. Although the main antiatherosclerotic function of HDL is thought to be its ability to promote the reverse transport of cholesterol from atherosclerotic lesions, HDL possesses several pleiotropic properties, such as anti-inflammation, antioxidation, antithrombosis, and vasorelaxation, 5, 6 and these antiatherosclerotic properties have been attributed to proteins and lipids riding on HDL.
Sphingosine-1-phosphate (S1P) is a bioactive lysophospholipid mediator. [7] [8] [9] A unique characteristic of S1P is that about two thirds of this important bioactive lipid in plasma is carried on HDL, followed by albumin. 10 Considering the bioactivities of S1P and HDL that have been elucidated from basic research, S1P is believed to contribute to many of the cardioprotective properties of HDL, such as antiapoptosis, 11 anti-inflammation, 12, 13 vasorelaxation, 14 and the maintenance of vascular permeability. 15, 16 Actually, although only limited studies presently exist, the plasma S1P level and the HDLlinked S1P level are known to be lower in subjects with coronary artery diseases. 17, 18 Moreover, recent studies have revealed that apolipoprotein M (apoM), a minor apolipoprotein on HDL, 19 is a carrier and a modulator of S1P.
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Makoto Kurano, Masumi Hara, Hitoshi Ikeda, Kazuhisa Tsukamoto, Yutaka Yatomi apoM-containing lipoprotein using apoE as a ligand. 24 About the quantity of HDL, CETP (cholesteryl ester transfer protein) exerts crucial influences; CETP transfers cholesteryl ester from HDL to apoB-containing lipoproteins, although it transfers triglycerides from apoB-containing lipoproteins to HDL. 25, 26 Therefore, individuals lacking CETP have an extremely high level of HDL, and CETP inhibitors increase the HDL cholesterol level. 27 CETP is a protein characteristic to human subjects, whereas mice lack CETP, and rats have lower levels of CETP. Although CETP might promote the reverse transport system to prevent atherosclerotic diseases, its (patho)physiological significance remained controversial. 28, 29 Contrary to the importance of CETP in the metabolism of HDL, Karuna et al 30 reported that the S1P and apoM levels were not elevated in total plasma samples from subjects with CETP deficiency. Because the HDL level was elevated although the plasma S1P level remained unaltered, the potency of eNOS (endothelial nitric oxide synthase) induction per each HDL was reduced in subjects with CETP deficiency. 31 At present, however, the mechanism by which CETP modulates the dynamisms and functions of S1P and apoM has not yet been fully elucidated. Therefore, in this study, we investigated the influence of CETP overexpression on the metabolism of S1P and apoM and the biological properties of S1P in mice originally lacking CETP.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Adenoviral CETP Overexpression Did Not Modulate Either the Total S1P or the ApoM Level in Murine Plasma
Using adenoviral gene transfer, we overexpressed CETP in mice that did not originally express CETP so as to investigate the influence of CETP on the dynamism of S1P and apoM. As shown in Figure 1A and Supplemental Figure IVA Analyses were performed after subjecting the mice to a 6-h fast on the fifth day after infection (n=5-11 per group). A, CETP activity. The serum samples from normolipidemic human subjects were used as a control (n=10). *P<0.01 vs PBS, null, and CETP (high), **P<0.01 vs other group. B, Plasma S1P levels. C and D, Plasma apolipoprotein levels were determined using a Western blot, and the intensities of the bands were quantified using Image J using albumin as a control. E, Plasma samples were pooled together and subjected to a fast protein liquid chromatography (FPLC) analysis for an analysis of the S1P distribution. F, The lipoprotein fractions were separated using an ultracentrifugation method for an analysis of the S1P distribution (n=4 per group). *P<0.01 vs the other group, **P<0.01 vs null. HDL indicates high-density lipoprotein; LDL, low-density lipoproteins; Lp-dep, lipoprotein-depleted fraction; and VLDL, very-low-density lipoprotein.
with adenovirus coding CETP depending on the extent of adenoviral infection. As shown in Figure IVB and IVC in the online-only Data Supplement, the plasma total cholesterol and triglycerides levels increased remarkably in CETP (high) mice, whereas the cholesterol levels in the apoB-containing fractions increased and those in the HDL fractions decreased in both CETP (low) mice and CETP (high) mice ( Figure IVD in the online-only Data Supplement).
About the plasma S1P and apoM levels, the S1P and apoM levels in the total plasma were not modulated by the overexpression of CETP ( Figure 1B through 1D) , whereas the plasma apo AI level decreased in CETP (high) mice ( Figure 1C ; Figure IVE in the online-only Data Supplement).
Adenoviral CETP Overexpression Shifted ApoM and S1P From HDL to ApoB-Containing Lipoproteins
We next examined the distribution of S1P in HDL purified by fast protein liquid chromatography from plasma from CETP (null), CETP (low), and CETP (high) mice. The majority of both S1P and apoM levels were confined to the HDL fraction in wild-type mice as reported previously, [20] [21] [22] 32 whereas the distributions of S1P and apoM were shifted to the verylow-density lipoprotein (VLDL)/intermediate-density lipoprotein (IDL) fractions, depending on the expression level of CETP ( Figure 1E ; Figure VA and VB in the online-only Data Supplement). This result suggests that S1P and apoM are carried on VLDL/IDL in CETP-overexpressing mice.
We also isolated lipoproteins using an ultracentrifugation method and observed a similar result; both the S1P and apoM levels in the VLDL/IDL and LDL fractions increased, whereas those in the HDL fraction decreased in CETP-overexpressing mice ( Figure 1F ; Figure VC and VD in the online-only Data Supplement). Interestingly, the levels of both S1P and apoM in the lipoprotein-depleted fraction slightly decreased in CETP-overexpressing mice, probably reflecting the mixture of a small amount of HDL in the lipoprotein-depleted fraction. At any rate, these results indicate that CETP does not alter the total plasma S1P or apoM concentration but modulates the distribution of S1P and apoM among lipoprotein fractions.
C 17 S1P Bound to ApoM-Containing Lipoprotein Was Abruptly Transferred to ApoB-Containing Lipoproteins in CETP-Overexpressing Mice
Next, we investigated whether CETP transfers S1P from apoMcontaining lipoprotein to apoB-containing lipoproteins. We administered C 17 S1P bound to human apoM-containing lipoproteins, prepared as described in the Materials and Methods section, into null mice or CETP (high) mice and then collected plasma samples consequently at 1 and 20 minutes after administration.
Concordant with the endogenous S1P and apoM levels, the time courses of both C 17 S1P and human apoM levels in the Figure 2 . Effects of CETP (cholesteryl ester transfer protein) overexpression on the distribution of C 17 S1P and apoM administered exogenously. Ten-wk-old male C57BL/6 mice were infected with control adenovirus (Null) or adenovirus coding CETP (CETP [high]). After a 6-h fast on the fifth day after infection, C 17 S1P bound to apoM-containing lipoproteins was administered via the tail vein. The analyses were performed at 1 and 20 min after administration. A, Time course of C 17 S1P in total plasma (n=10 per group). B and C, Plasma levels of exogenously administered human apoM. Albumin was used as a control (n=5-6 per group). D, Distribution of C 17 S1P among fast protein liquid chromatography (FPLC) fractions. E-I, Time course for C 17 S1P (E-H) and human apoM (I) for each lipoprotein fraction or lipoprotein-depleted fraction (Lp-dep; n=6 per group). *P<0.01 vs null, †P<0.01, ‡P<0.05 vs the corresponding level at 1 min. HDL indicates high-density lipoprotein; LDL, low-density lipoproteins; and VLDL, very-low-density lipoprotein.
total plasma were not different between the null mice group and the CETP (high) mice group (Figure 2A through 2C) , whereas other lipid profiles were not altered (Figure VIA through VIE in the online-only Data Supplement). Although most of the C 17 S1P and apoM were distributed to the HDL and lipoproteindepleted fractions, and not to apoB-containing fractions, before administration ( Figure II in the online-only Data Supplement), the exogenously administered C 17 S1P and apoM were distributed to apoB-containing fractions in CETP (high) mice within 1 minute after the injection (Figure 2D through 2I; Figure  VIF in the online-only Data Supplement). At 20 minutes after administration, the distribution patterns of C 17 S1P and apoM were similar to those at 1 minute, whereas the clearance rates of C 17 S1P on VLDL/IDL and LDL seemed to be rather higher in CETP-overexpressing mice than in null mice ( Figure 2E through 2G). When we administered C 17 S1P using albumin as a vehicle, we observed that much smaller amount of C 17 S1P was transferred to lipoproteins (Figure VII in the online-only Data Supplement), suggesting that apoM-containing lipoproteins might have important roles in the redistribution of C 17 S1P.
C 17 S1P Bound to HDL Shifted to LDL Ex Vivo Independently of the Presence of CETP
Although the results of the experiments described so far have demonstrated that S1P shifted from HDL to apoB-containing lipoproteins in CETP-overexpressing mice, whether CETP is directly involved in the redistribution of S1P remained unclear. Therefore, we next investigated whether CETP is necessary for this redistribution using ex vivo experiments. Interestingly, as shown in Figure 3A , when C 17 S1P bound to HDL was mixed with LDL, C 17 S1P shifted to LDL independently of the presence of CETP; the shift was dependent on the amount of LDL, although CETP significantly affected the distribution of cholesterol and triglycerides ( Figure VIIIA and VIIIB in the online-only Data Supplement). When we investigated whether a CETP inhibitor affected the shifting of C 17 S1P from HDL to LDL in the presence of plasma from CETP (high) mice or human plasma, we observed no modulation of the distribution by the CETP inhibitor ( Figure 3B and 3C) , although the CETP inhibitor significantly affected the distribution of cholesterol and triglycerides ( Figure  VIIIC through VIIIF in the online-only Data Supplement). These results suggest that CETP did not directly transfer C 17 S1P but that CETP altered the distribution of lipids among lipoproteins, which might have affected the distributions of C 17 S1P and apoM.
Distribution of ApoM Was Shifted to the HDL Fraction in CETP-Deficient Subjects
Because the cholesterol levels in the VLDL/IDL fractions were much higher in CETP-overexpressing mice than those in the human lipid profiles, we next investigated the distribution of apoM in a human CETP-deficient subject (CETP activity, −1.6 Fluorescence Intensity Units) and a corresponding hypercholesterolemia subject (CETP activity, 138 Fluorescence Intensity Units). As shown in Figure 4 , apoM was distributed mainly to the same fractions as apo AI in the CETP-deficient subject (fraction 32-41), whereas apoM was detected in apo AI-poor fractions (fractions 28-33) and apo AI-rich fractions (fractions 40-47) in the corresponding hypercholesterolemia subject. The distribution of plasma S1P among lipoproteins in the CETP-deficient subject and the average of subjects with hypercholesterolemia (n=3) are 7.2 nmol/L and 17.4±11.3 nmol/L in VLDL/IDL, 13.4 nmol/L and 56.7±23.0 nmol/L in LDL, 629 nmol/L and 300±62.2 nmol/L in HDL, and 131 nmol/L and 148±17.1 nmol/L in lipoprotein-depleted fractions, respectively. Although limited subjects have been studied, these results suggest that CETP might modulate the distribution of apoM/S1P among lipoproteins in human subjects.
S1P Residing in ApoB-Containing Lipoproteins Activated Human Umbilical Vein Endothelial Cells to a Greater Degree Than S1P Residing in HDL
Because S1P is a bioactive lipid mediator, we compared the bioactivities of S1P riding on HDL and apoB-containing lipoproteins. We prepared a medium containing each lipoprotein separated from CETP (high) mice or null mice. The S1P contents of each medium were 105 nmol/L in VLDL/IDL separated from CETP (high) mice (CETP-VLDL/IDL), 60 nmol/L in LDL separated from CETP (high) mice (CETP-LDL), and 125 nmol/L in HDL separated from null mice (null-HDL), respectively, and the apoM contents are shown in Figure IX in the online-only Data Supplement; both the S1P and apoM contents were slightly higher in the null-HDL fraction than in the CETP-VLDL/IDL or CETP-LDL fractions. We investigated the induction of Akt (AKT8 virus oncogene cellular homolog) and eNOS phosphorylation by CETP-VLDL/IDL or null-HDL in human umbilical vein endothelial cells (HUVECs), which express S1P receptors ( Figure X in the online-only Data Supplement) as reported previously, 33, 34 with or without VPC23019 (VPC), an antagonist against S1P receptors 1 and 3. Interestingly, about Akt, the magnitude of phosphorylation was greater in the HUVECs treated with CETP-VLDL/IDL than in those treated with null-HDL ( Figure 5A and 5B), whereas the phosphorylation level was not different between these groups when treated with VPC. The phosphorylation of Akt was dependent on the concentration of CETP-VLDL/IDL and null-HDL, the S1P levels of which being 152 nmol/L and 204 nmol/L, respectively, and was significantly greater in HUVECs treated with CETP-VLDL/ IDL than those with null-HDL ( Figure XI in the online-only Data Supplement). Concordant with these results, more potent induction of phosphorylation of eNOS was observed when HUVECs were treated with CETP-VLDL/IDL ( Figure 5C and 5D); the effect of VPC was reproduced as was the case with Akt phosphorylation (Figure 5E and 5F). Therefore, S1P on VLDL/IDL might have more potent properties on the phosphorylation of Akt and eNOS in HUVECs.
Effects of the Redistribution of S1P on the Cholesterol Contents in Plasma, Liver, and Bile
We next investigated whether S1P redistribution might affect the dynamisms of cholesterol. We measured lipid components in plasma, liver, and bile collected from CETP (high) mice and null mice with or without VPC and found that VPC did not modulate the contents of cholesterol, campesterol, and sitosterol in plasma, liver, and bile (Figure 5G and 5I ; Tables I through III in the online-only Data Supplement). We also observed that VPC did not modulate the fast protein liquid chromatography profile of cholesterol ( Figure XII in the online-only Data Supplement). These results suggest that the redistribution of S1P among lipoproteins might affect other antiatherosclerotic effects (than the reverse transport of cholesterol), such as activation of eNOS.
S1P Residing in ApoB-Containing Lipoproteins Ameliorates Glucose Metabolism to a Greater Degree Than S1P Residing in HDL
We further compared the induction of insulin secretion from MIN6 cells by S1P on each lipoprotein fraction because MIN6 expressed S1P receptors (Figure XIII in the online-only Data Supplement) and S1P, at least S1P bound to HDL, is reported to induce insulin secretion in a manner dependent on S1P receptor 1 or 3. [35] [36] [37] As shown in Figure 6A , although S1P on each of the lipoproteins induced insulin secretion, MIN6 cells treated with CETP-VLDL/IDL or CETP-LDL for 30 minutes tended to induce insulin secretion to a greater degree than null-HDL. When the cells were treated with VPC, their ability to promote insulin secretion was diminished. We observed a similar result when we treated MIN6 cells with lipoproteins with or without VPC in 10 minutes ( Figure XIV in the online-only Data Supplement). These results also suggested that S1P on apoB-containing lipoproteins might have a stronger bioactive potency than S1P on HDL.
We next investigated the modulation of glucose metabolism by the redistribution of S1P among lipoproteins by CETP. We performed a glucose tolerance test in CETP (high) mice and null mice with or without VPC. As shown in Figure 6B through 6D and Figure XVA in the online-only Data Supplement, we found that CETP overexpression increased glucose tolerance and insulin secretion, which was reversed by the treatment with VPC. When we performed an insulin tolerance test, we A serum sample from a CETPdeficient subject or a corresponding hypercholesterolemia subject was subjected to fast protein liquid chromatography (FPLC) analysis, and the distribution of apolipoproteins among the FPLC fractions was determined using a Western blot. A, The distribution of total cholesterol levels. B and C, The distribution of apolipoprotein levels. LDL indicates lowdensity lipoprotein.
observed that CETP overexpression increased insulin sensitivity, which was inhibited by VPC ( Figure 6E ; Figure XVB in the online-only Data Supplement). These results suggest that the redistribution of S1P mediated by CETP enhanced glucose tolerance and insulin sensitivity in vivo.
Discussion
The distribution of S1P in the plasma is unique compared with those of other lipid mediators; two thirds of S1P in plasma is carried on HDL through apoM, whereas most other bioactive lipids are circulated in the blood using albumin as a vehicle. Therefore, the concentration of S1P is largely affected by proteins involved in the dynamism of lipoproteins, especially HDL. About the metabolism of HDL, CETP is thought to play a crucial role. CETP transfers cholesterol from HDL to apoBcontaining lipoproteins; therefore, CETP is one of the strongest determinants of the circulating HDL level. 38 Despite this important role of CETP, neither the apoM nor the S1P level in total plasma was reportedly elevated in CETP-deficient subjects. 30 Concordant with this previous study, in this study using mice overexpressing CETP, we found that CETP did not modulate either the apoM or the S1P level in the total plasma ( Figure 1B through 1D) . However, we observed that the distributions of apoM and S1P were shifted from HDL fractions .01 vs null-HDL with VPC, none, and none with VPC, **P<0.01 vs null-HDL with VPC, CETP-VLDL/IDL with VPC, none, and none with VPC. G-I, Ten-wk-old male C57BL/6 mice were infected with control adenovirus (Null) or adenovirus coding CETP (CETP) and intraperitoneally challenged with the vehicle alone or with VPC (0.75 mg/kg body weight) twice a day from the second day after the viral administration. Then the mice were subjected to a fast for 6 h and the cholesterol contents in plasma, liver, and bile were determined with an high-performance liquid chromatography method (n=5 per group). to apoB-containing fractions in CETP-overexpressing mice (Figure 1E and 1F; Figure V in the online-only Data Supplement). Kinetic studies administering C 17 S1P bound to apoM-containing lipoproteins suggested that C 17 S1P and apoM were swiftly transferred from HDL to apoB-containing lipoproteins (Figure 2 ). Although the mechanism for the redistribution of S1P and apoM remains to be elucidated, CETP might not directly affect the redistribution, but the modulation of the lipid profiles by CETP might affect the distribution of S1P and apoM ( Figure 3) ; when we incubated HDL containing C 17 S1P with 497 µg of LDL, more C 17 S1P was transferred to LDL than when we incubated with 83 µg of LDL ( Figure 4A ), suggesting that the quantity of LDL is important in the transference of S1P. In addition to the quantity of LDL, CETP can modulate the lipid composition of LDL. The influence of the lipid composition of LDL on its capacity to bind apoM/S1P is also an important task to be clarified.
CETP inhibitors are expected to be novel medicines for the treatment of subjects with low HDL cholesterol levels who are prone to experience atherosclerotic diseases. 27 At present, however, CETP inhibitors are not considered to protect against atherosclerotic diseases successfully, at least as successfully as expected. 39 Possibly, the inhibition of CETP might prevent the reverse transport of cholesterol from peripheral tissues to liver, and CETP inhibitors might somehow elevate blood pressure. 40 Along with the important role of HDL in the reverse transport system, recent studies have suggested the possible existence of pleiotropic effects of HDL, and S1P is thought to be attributable to at least some of these effects of HDL. 41, 42 Therefore, the results from this study demonstrating that CETP did not modulate the S1P and apoM levels in total plasma, whereas CETP decreased the HDL level to a great degree, suggest that another mechanism may account for the failure of the CETP inhibitor to exert antiatherosclerotic properties in addition to its inhibitory effects on the reverse transport of cholesterol; the CETP inhibitor might not be able to enhance the pleiotropic effects of HDL because it cannot increase the plasma S1P or apoM levels. Actually, a recent study demonstrated that HDL from subjects with CETP deficiency induces eNOS activation to a lesser degree, 31 supporting the idea proposed in this study.
Another interesting finding of this study is that C 17 S1P on VLDL/IDL and LDL seemed to be cleared more rapidly than that on HDL ( Figure 2D through 2H) . Recently, we reported that the LDL receptor is involved in the clearance of S1P and apoM carried on ApoE-rich HDL in mice. 24 In addition to this pathway, this study suggested that apoM and S1P could also be removed through the pathway by which apoB-containing lipoproteins are removed. Therefore, S1P, which is abundant on HDL in plasma, can be cleared from circulation through 2 pathways: one pathway is that S1P on HDL is cleared directly through apoE and LDL receptor and the other is that S1P on HDL is transferred to LDL by indirect effects of CETP and then cleared with LDL. Considering a previous report demonstrating that the dynamism of apoM is influenced by the LDL receptor-mediated clearance of apoB-containing particles 43 and the presence of CETP and a larger amount of LDL in human subjects, the pathway involving apoB-containing lipoproteins might be a major pathway in the clearance of S1P bound to apoM-containing lipoproteins.
Finally, we investigated the physiological significance of the redistribution of S1P by CETP in the fields of atherosclerosis and diabetes mellitus. First, we found that S1P riding on VLDL/LDL induced the phosphorylation of Akt and eNOS in HUVECs to a greater degree than S1P on HDL, in a manner sensitive to the S1P receptor 1 or 3 antagonist VPC, although the treatment with VPC did not modulate cholesterol levels in plasma, liver, and bile ( Figure 5 ). Although we could not exactly investigate the effects on reverse transport system with a radioisotope assay, these results suggest that the redistribution of S1P by CETP might not affect the reverse transport of cholesterol but affect other antiatherosclerotic effects, such as vasorelaxation by the activation of eNOS, considering together with the previous reports demonstrating that the activation of S1P receptor 1 44 or apoM overexpression 23 prevented atherosclerosis in vivo. About diabetes mellitus, we observed that S1P on apoB-containing lipoproteins induced insulin secretion to a greater degree than S1P on HDL and that CETP overexpression increased glucose tolerance and insulin sensitivity, which was reversed by the treatment with VPC ( Figure 6 ). The effects of CETP on insulin secretion and insulin sensitivity are controversial at present; it has been reported that CETP overexpression ameliorates, 45 deteriorates, 46 or fails to modulate 47, 48 these antidiabetic reactions and that a CETP inhibitor improves glucose metabolism in animal experiments. 49 The difference between this study and the previous studies might be because of the duration of CETP modulation; we overexpressed CETP for 5 days, whereas others investigated the effects of CETP overexpression or a CETP inhibitor on glucose metabolism for a longer term. Along with the redistribution of S1P, CETP or lipoprotein profiles influenced by CETP, of course, might modulate the reverse transport of cholesterol from cells involved in glucose metabolism, such as pancreatic β-cells, which can largely affect glucose metabolism. At least, however, we can safely conclude that the results from this study suggest the redistribution of S1P by CETP might enhance the physiological properties of plasma S1P on glucose metabolism.
Recently, we and others demonstrated the possible different physiological properties of S1P depending on its carrier; S1P bound to apoM on HDL had a greater effect in maintaining the endothelial barrier 50 and in secreting insulin from pancreatic β-cells, 37 whereas S1P carried on apoM had a suppressive effect on the proliferation of lymphocytes 51 and the inflammation of endothelial cells. 52 This study suggests that S1P carried on apoB-containing lipoproteins might have some distinct properties from S1P carried on albumin or HDL; however, the physiological importance of this phenomenon in human subjects is unclear because the amount of S1P carried on apoB-containing lipoproteins is relatively small, 53 and the mechanism responsible for the differences in the bioactivities of S1P depending on its carriers remains to be elucidated. Further studies are necessary to elucidate the mechanism for the carrier-dependent properties of S1P and the significance of S1P carried on apoB-containing lipoproteins.
In conclusion, CETP does not modulate the S1P and apoM contents in total plasma, although CETP shifts the distribution of S1P and apoM from HDL to apoB-containing lipoproteins, on which S1P might exert more potent bioactivities but is removed more rapidly.
